IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,490,620 | +11.2% | 32,862 | +0.6% | 0.11% | +17.0% |
| Q2 2023 | $1,340,819 | +16.2% | 32,679 | +1.2% | 0.09% | +16.0% |
| Q1 2023 | $1,153,830 | -2.9% | 32,284 | +2.6% | 0.08% | -6.9% |
| Q4 2022 | $1,188,773 | -7.8% | 31,474 | +8.3% | 0.09% | -17.1% |
| Q3 2022 | $1,290,000 | +22.9% | 29,071 | +2.8% | 0.10% | +26.5% |
| Q2 2022 | $1,050,000 | +1.0% | 28,276 | +1.0% | 0.08% | +16.9% |
| Q1 2022 | $1,040,000 | +28.4% | 28,001 | +4.6% | 0.07% | +36.5% |
| Q4 2021 | $810,000 | +11.0% | 26,771 | +23.4% | 0.05% | +2.0% |
| Q3 2021 | $730,000 | -13.1% | 21,691 | +3.0% | 0.05% | -12.1% |
| Q2 2021 | $840,000 | -8.7% | 21,053 | +3.4% | 0.06% | -15.9% |
| Q1 2021 | $920,000 | -17.1% | 20,353 | +3.6% | 0.07% | -20.7% |
| Q4 2020 | $1,110,000 | +23.3% | 19,642 | +3.2% | 0.09% | +7.4% |
| Q3 2020 | $900,000 | -18.2% | 19,037 | +1.8% | 0.08% | -23.6% |
| Q2 2020 | $1,100,000 | +34.1% | 18,701 | +7.9% | 0.11% | +9.3% |
| Q1 2020 | $820,000 | -18.6% | 17,336 | +4.0% | 0.10% | +5.4% |
| Q4 2019 | $1,007,000 | +6.2% | 16,676 | +5.4% | 0.09% | -1.1% |
| Q3 2019 | $948,000 | +0.6% | 15,821 | +8.0% | 0.09% | 0.0% |
| Q2 2019 | $942,000 | -16.2% | 14,651 | +5.8% | 0.09% | -20.5% |
| Q1 2019 | $1,124,000 | +51.3% | 13,843 | +0.7% | 0.12% | +33.0% |
| Q4 2018 | $743,000 | +6.1% | 13,744 | +1.2% | 0.09% | +22.2% |
| Q3 2018 | $700,000 | +24.8% | 13,579 | +0.8% | 0.07% | +16.1% |
| Q2 2018 | $561,000 | -4.9% | 13,469 | +0.6% | 0.06% | -6.1% |
| Q1 2018 | $590,000 | -14.2% | 13,389 | -2.0% | 0.07% | -9.6% |
| Q4 2017 | $688,000 | +1.5% | 13,669 | +2.2% | 0.07% | -3.9% |
| Q3 2017 | $678,000 | +4.0% | 13,379 | +4.4% | 0.08% | -1.3% |
| Q2 2017 | $652,000 | +33.9% | 12,809 | +5.7% | 0.08% | +28.3% |
| Q1 2017 | $487,000 | -15.0% | 12,119 | +1.1% | 0.06% | -18.9% |
| Q4 2016 | $573,000 | +50.4% | 11,984 | +15.2% | 0.07% | +48.0% |
| Q3 2016 | $381,000 | +46.5% | 10,404 | -7.0% | 0.05% | +38.9% |
| Q2 2016 | $260,000 | -25.5% | 11,184 | +29.9% | 0.04% | -29.4% |
| Q1 2016 | $349,000 | +4.8% | 8,610 | +60.2% | 0.05% | 0.0% |
| Q4 2015 | $333,000 | – | 5,375 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |